Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 5/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89415 | 0.92 | EGFR (0.41) | EGFRERBB2ARMAOAMAOB | |
| SCHEMBL430108 | 0.90 | EGFR (0.47) | EGFRERBB2ARMAOAMAOB | |
| SCHEMBL2774024 | 0.84 | HPGD (0.49) | EGFRARMAOAMAOBSMN1; SMN2 | |
| SCHEMBL13581220 | 0.83 | ALDH1A1 (0.55) | ARSMN1; SMN2 | |
| SCHEMBL30108128 | 0.82 | PDE4B (0.46) | ARMAOAMAOBAAK1IDH1 | |
| SCHEMBL16279970 | 0.82 | PDE4B (0.46) | ARMAOAMAOBAAK1IDH1 | |
| SCHEMBL14820128 | 0.82 | MAOB (0.42) | ARMAOAMAOBAAK1 | |
| SCHEMBL8432254 | 0.82 | AR (0.47) | AR | |
| SCHEMBL29363898 | 0.81 | EGFR (0.44) | EGFRERBB2ARMAOAMAOB | |
| SCHEMBL746850 | 0.81 | EGFR (0.44) | EGFRERBB2ARMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041821-B1 | BICYLIC COMPOUNDS AS MODULATORS OF RORGAMMA | BOEHRINGER INGELHEIM INT (DE) | 2018-05-30 | — | — | EP | disclosed |
| US-9745267-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745297-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745297-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745267-B2 | Compounds as modulators of RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160251310-A1 | COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160251310-A1 | COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160159791-A1 | COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159791-A1 | COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| WO-2015035032-A1 | BICYLIC COMPOUNDS AS MODULATORS OF RORGAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015017335-A1 | AZAINDOLE COMPOUNDS AS MODULATORS OF RORC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-05 | — | — | WO | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159791-A1 | COMPOUNDS AS MODULATORS OF RORC | RORC, RORB, RORA | EGFR 2578/4885ERBB2 2359/4885AR 418/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | EGFR 489/4885ERBB2 309/4885AR 1363/4885 |
| US-20160251310-A1 | COMPOUNDS AS MODULATORS OF RORC | RORC, RORB, RORA | EGFR 2525/4885ERBB2 2327/4885AR 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.